试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
编号:NCT02031419登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:CC-122、CC-223、Rituximab、CC-122
登记的停止原因(原文):Replaced with another clinical trial.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
Ultrasound Monitoring of Abdominal Soft Tissue
编号:NCT02722616登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Ultrasound scan of the pancreas、Ultrasound scan of the Liver、Reference ultrasound
登记的停止原因(原文):Ultrasound vendor cannot support the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
编号:NCT02829723登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:BLZ945、PDR001
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
编号:NCT04145037登记状态:提前终止企业 / 申办者:AVROBIO
药物 / 成分:AVR-RD-02
登记的停止原因(原文):This study was voluntarily terminated by the sponsor to halt development and was not based on any safety or medical reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
编号:NCT04327999登记状态:提前终止企业 / 申办者:Vanderbilt-Ingram Cancer Center
药物 / 成分:Artificial Tears
登记的停止原因(原文):Funding ended
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
编号:NCT04339413登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Gantenerumab
登记的停止原因(原文):Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
编号:NCT04536350登记状态:提前终止企业 / 申办者:Prof. Dr. Jörg Leuppi
药物 / 成分:Aviptadil 67μg、Placebo 0.9% NaCl solution
登记的停止原因(原文):Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients. Continuous screening has been carried out but none of the patients met the eligibility criteria for the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-18
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
编号:NCT05154630登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
药物 / 成分:TQB2858 injection
登记的停止原因(原文):The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-17
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
编号:NCT01898793登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Fludarabine、Cyclophosphamide、Leukapheresis、Cytokine-induced killer cells
登记的停止原因(原文):Insufficient funding/staff
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-17
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
编号:NCT03443973登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Gantenerumab、Placebo
登记的停止原因(原文):Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
查看官方原始记录 ↗